REGENXBIO Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- REGENXBIO's estimated annual revenue is currently $218.5M per year.
- REGENXBIO received $201.8M in venture funding in August 2018.
- REGENXBIO's estimated revenue per employee is $788,827
- REGENXBIO's total funding is $247M.
- REGENXBIO has 277 Employees.
- REGENXBIO grew their employee count by 1% last year.
- REGENXBIO currently has 23 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
What Is REGENXBIO?
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adenoassociated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and thirdparty NAV Technology Platform licensees.keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
Number of Employees
Employee Growth %
|Ken Mills||President & Chief Executive Officer||Email Available|
|Kenneth Mills||CEO/President||Email Available|
|Vit Vasista||CFO||Email Available|
|Sara Garon Berl||Vice President, Law And Policy||Email Available|
|Ken Trout||Director Data Management||Email Available|
|Anahita Nikzad||Director Clinical Operations||Email Available|
|Amanda Fleming||Conference Project Manager||Email Available|
|Matthew Carney||Director of Data Management||Email Available|
|Paul Broberg||Facilities Manager||Email Available|
|Avanti Ghanekar||Director Of Clinical Development||Email Available|
RegenxBio Inc. just locked in another deal — this one with a company working to treat eye diseases. The Rockville biotech has reached a ...
REGENXBIO expands RGX-314 gene therapy program to evaluate Clearside's proprietary, in-office SCS Microinjector™ platform targeting ...
ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to ...
REGENXBIO Executive Hires
|2014-10-29||Stephen Yoo||Chief Medical Officer||Article|